Construction of the RNA Facility has been accomplished on time marking a new period within the state’s skill to translate, develop and manufacture life-saving RNA therapeutics.
This RNA Facility will place NSW in a robust place within the struggle towards present and rising ailments by bolstering home RNA manufacturing functionality, attracting funding, creating native jobs and fostering collaboration between universities, analysis institutes and business.
The COVID‑19 pandemic underscored the pressing want for Australia to have native functionality to quickly develop and manufacture vaccines and therapeutics. With world provide chains stretched and worldwide provide restricted, the new RNA Facility ensures NSW is best ready for future pandemics by enabling the quick manufacturing of RNA vaccines and therapies when they’re wanted most.
Located throughout the Macquarie University Innovation Precinct, the RNA Facility contains superior laboratories and support areas that may make it the one web site in Australia able to producing a variety of new and current RNA therapeutics beneath one roof. Industry accomplice and operator Aurora Biosynthetics will now have interaction with researchers and shoppers who goal to advance their therapeutic innovations from the laboratory in the direction of medical trials.
In addition to vaccines, the functions of RNA expertise are numerous, starting from therapies for cancers and uncommon genetic ailments to pest‑management options for agricultural use.
The NSW Government plans to present an extra $119 million over 10 years in support of RNA R&D initiatives on the RNA Facility, and in July final 12 months, launched the $17.6 million NSW RNA Research and Training Network together with the $6 million RNA Pipeline Grants Program.
The undertaking was delivered by Health Infrastructure in collaboration with the Office of the Chief Scientist & Engineer. RNA Australia led by Chair Kate Pounder and Chief Executive Officer Paul McDonald will present ongoing engagement with the Australian educational neighborhood together with Aurora Biosynthesis. Ownership of the Facility will now switch to Property & Development NSW.
Minister for Health and Regional Health Ryan Park mentioned:
“This a significant step ahead for the way forward for healthcare in NSW and a chance for us to develop and deploy new superior well being therapies.
“This facility is an exciting new link between NSW’s world-class RNA researchers, our outstanding clinical trials capability and the health system.”
Minister for Innovation, Science and Technology Anoulack Chanthivong said:
“The opening of this facility is a major milestone for NSW and a proud moment for our innovation sector. It gives our researchers, clinicians and industry partners a place where ideas can move rapidly from the lab bench to real‑world solutions that improve lives.
“We all saw during COVID‑19 how quickly global conditions can change, and how vital it is to have the capability to develop vaccines and treatments here at home. This facility strengthens NSW’s resilience and ensures we can respond faster and more effectively to future health threats.
“By bringing together cutting‑edge equipment, world‑leading expertise and strong industry partnership under one roof, this centre puts NSW at the forefront of RNA medicine and opens the door to new breakthroughs, new jobs and new opportunities across health, biotech and agriculture.”
Minister for Medical Research, David Harris said:
“This facility brings collectively NSW’s world-class RNA and supply expertise analysis with our excellent medical trials functionality.
“The facility will become a cornerstone of NSW’s RNA research ecosystem, following previous important NSW Government investments, including the NSW RNA Production & Research Network, the UNW RNA Institute and Australia’s first Viral Vector Manufacturing Facility at Westmead Health and Innovation District.
“We know how important it is to provide the sovereign capability needed to develop, test and manufacture life-saving treatments right here in NSW.
“From next-generation vaccines to transformative treatments for cancer and rare genetic diseases, the potential of RNA technology, for both humans and animals, is limitless.”
Dr Daniel Getts, Founder and Chair of Aurora Biosynthetics, the operator of the power, and CEO of Create Medicines mentioned:
“This has been a big cross-team effort – combining the NSW Government’s imaginative and prescient, strategic path and sources with Aurora Biosynthetics’ ingenuity, know-how and entrepreneurial spirit.
“This is a moment to celebrate government stewardship of resources for the betterment of the public.
“The facility opens an even broader channel for Australian researchers and clinicians who can gain support for their ideas, to innovate and accelerate new therapies to patients.”
Paul McDonald, CEO, RNA Australia said:
“By establishing a world-class RNA manufacturing hub right here in NSW, we are ensuring our local researchers no longer have to head overseas. We are providing the infrastructure to realise life-saving medicinal breakthroughs right here in our own backyard.”
Macquarie University Vice-Chancellor Professor S Bruce Dowton mentioned:
“Macquarie University is proud to host this new RNA facility and to assist deliver it to life at a time of extraordinary world momentum in biomedical science.
“RNA technologies are transforming how we understand, prevent and treat disease, with the potential to reshape healthcare for generations to come.
“This facility will play a vital role in strengthening Australia’s capabilities in this critical field, while also adding to a thriving medical and research precinct here at Macquarie Park.”